These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25734799)

  • 21. AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report.
    Miyazaki D; Yazaki M; Gono T; Kametani F; Tsuchiya A; Matsuda M; Takenaka Y; Hosh Y; Ikeda S
    Amyloid; 2008 Jun; 15(2):125-8. PubMed ID: 18484339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
    J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
    Bellotti V; Mangione P; Merlini G
    J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
    Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
    Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exceptional oral manifestations of amyloid light chain protein (AL) systemic amyloidosis.
    Elad S; Czerninski R; Fischman S; Keshet N; Drucker S; Davidovich T; Goldschmidt N
    Amyloid; 2010 Mar; 17(1):27-31. PubMed ID: 20146645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
    Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
    PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
    Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
    Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloidogenic light chains impair plasma cell survival.
    Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
    Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing.
    Kaul E; Pilichowska M; Vullaganti M; Madan N; Comenzo RL
    Amyloid; 2014 Mar; 21(1):62-5. PubMed ID: 24256111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?
    Bézard M; Zaroui A; Kharoubi M; Lam F; Poullot E; Teiger E; Agbulut O; Damy T; Kordeli E
    Amyloid; 2024 Sep; 31(3):209-219. PubMed ID: 38973117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precise diagnosis and typing of early-stage renal immunoglobulin-derived amyloidosis by label-free quantification of parallel reaction monitoring-based targeted proteomics.
    Li Y; Zhang Y; Zhou X; Xue X; Wang M; Kang D; Zhou Y; Hu R; Quan S; Xing G; Yang J
    BMC Nephrol; 2023 Mar; 24(1):50. PubMed ID: 36894904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
    Gertz MA; Comenzo R; Falk RH; Fermand JP; Hazenberg BP; Hawkins PN; Merlini G; Moreau P; Ronco P; Sanchorawala V; Sezer O; Solomon A; Grateau G
    Am J Hematol; 2005 Aug; 79(4):319-28. PubMed ID: 16044444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical characterization of amyloid derived from the variable region of the kappa light chain subgroup III.
    Picken MM; Gallo GR; Pruzanski W; Frangione B
    Arthritis Rheum; 1990 Jun; 33(6):880-4. PubMed ID: 2114114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
    Arbustini E; Gavazzi A; Merlini G
    Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.